Jeanine (Dienogest, Ethinylestradiol)

Dienogest and ethinylestradiol act on the hypothalamic‑pituitary‑gonadal axis. They inhibit the release of luteinising hormone and follicle‑stimulating hormone, preventing follicular maturation and ovulation. The estrogen component stabilises the endometrium, while the progestogen thickens cervical mucus and creates an environment that is unfavorable for sperm penetration and implantation.

The specific dosing regimen for Jeanine is determined by the prescribing clinician based on the product’s approved labeling and the patient’s individual health profile. Typically, combined oral contraceptives are taken once daily for a defined cycle, but the exact number of tablets and schedule should be confirmed by a qualified healthcare professional.

Jeanine is intended for use only when a woman is not pregnant. If pregnancy occurs, the product should be discontinued immediately. Safety data for use during breastfeeding are limited; therefore, healthcare providers usually advise against using combined oral contraceptives while nursing unless the benefits outweigh potential risks.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity of Jeanine. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Jeanine contains dienogest, a progestogen with a relatively low androgenic profile, combined with ethinylestradiol. Compared with older formulations that use levonorgestrel or norethisterone, Jeanine may offer improved cycle control and a lower risk of certain androgen‑related side effects, while maintaining comparable contraceptive efficacy.

Jeanine tablets should be stored at ambient temperature, below 25 °C, in the original blister pack or container. Protect the product from excess moisture, heat and direct sunlight to maintain potency throughout its shelf life.

Jeanine is taken orally, usually once daily at the same time each day, following the regimen indicated on the product label (e.g., 21 active tablets followed by a hormone‑free interval). Patients should swallow the tablet whole with water and should not skip doses without consulting their prescriber.

The most serious adverse events associated with combined oral contraceptives include venous thromboembolism, arterial thrombosis (stroke or myocardial infarction), severe hypertension, liver disorders and rare allergic reactions. Patients should seek immediate medical attention if they experience symptoms such as sudden chest pain, shortness of breath, severe headache, visual changes or unexplained swelling.

Jeanine is contraindicated in women with a history of thromboembolic disorders, uncontrolled hypertension, active liver disease, known or suspected breast cancer, or those who are pregnant. It should also be avoided by smokers aged 35 years or older and by individuals taking medications that markedly increase clotting risk.